A Phase III Open-Label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion (Cutaneous Solution) in Hypogonadal Men to Evaluate Skin-safety
Latest Information Update: 06 Oct 2021
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Acrux
- 29 Jun 2011 Results published on the Clinical Endocrinology website.
- 04 Jan 2011 Eli Lilly added as company and lead trial centre as reported by ClinicalTrials.gov. (Extension trial: NCT00857454)
- 04 Jan 2011 Eli Lilly added as company and lead trial centre as reported by ClinicalTrials.gov. (Extension trial: NCT00857454)